About this Journal Submit a Manuscript Table of Contents
Leukemia Research and Treatment
Volume 2011 (2011), Article ID 410291, 2 pages
http://dx.doi.org/10.4061/2011/410291
Letter to the Editor

Myeloid Sarcoma: The Clinician's Point of View

1Department of Hematology, University of Brescia, P.le Spedali Civili 1, 25123 Brescia, Italy
2Division of Hematology and Bone Marrow Transplant, Azienda University Hospital, Santa Maria della Misericordia Square, 33100 Udine, Italy
3Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Via Lombroso 1, 61122 Pesaro, Italy

Received 27 January 2011; Accepted 10 February 2011

Copyright © 2011 M. Malagola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Myeloid Sarcoma may occur in patients with an acute or chronic myeloproliferative disorder as well as de novo, with no apparent sign or symptom of concomitant haematological disease. The patients are preferentially young male and the site of disease localization may vary from central nervous system to pleura and thorax, with a common involvement of the reticuloendothelial system. The disease often shows chromosomal rearrangements, involving chromosomes 7, 8 and 3 and sometimes a complex karyotype (more than 3 abnormalities) is detected at diagnosis. The prognosis of this disease is dismal and only high-dose chemotherapy with autologous or allogeneic stem cells transplantation (auto or allo-SCT) may be potentially curative. In the absence of definitive elements that can define the prognosis of extra-medullary localization of “standard risk” AML, Clinicians should pursue the collection of data from different Centres and design of homogeneous treatment strategies, that could integrate standard chemotherapy with specific approaches, such as radiotherapy, transplant procedures or, in selected cases (such as those displaying molecular abnormalities involving protein tyrosine-kinases), molecularly targeted therapies.